logo

GILD

Gilead Sciences·NASDAQ
--
--(--)
--
--(--)
3.99 / 10
Netural

Gilead Sciences' fundamental evaluation is rated neutral (4.0/10). Key strengths include solid Profit-MV (1.0834) and Cash-MV (0.6933) scores, while Revenue-MV (-0.2038) is a notable weakness. Other factors such as PB-ROE (1.3202) and Net income-Revenue (1.4379) show moderate performance. The inventory turnover ratio (2.6381) is efficient, but fixed assets turnover ratio (3.9432) is only average. Overall, the fundamentals present a mixed picture that constrains aggressive upside expectations.

Fundamental(3.99)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.20
Score1/3
Weight9.55%
1M Return7.18%
Inventory turnover ratio
Value2.64
Score2/3
Weight-2.21%
1M Return-2.32%
Gross profit margin (%)
Value78.58
Score2/3
Weight1.70%
1M Return1.56%
Profit-MV
Value1.08
Score2/3
Weight12.73%
1M Return9.53%
Net income-Revenue
Value1.44
Score3/3
Weight25.86%
1M Return14.20%
PB-ROE
Value1.32
Score2/3
Weight14.85%
1M Return11.15%
Fixed assets turnover ratio
Value3.94
Score2/3
Weight0.36%
1M Return0.33%
Asset-MV
Value-0.50
Score2/3
Weight23.27%
1M Return15.08%
Cash-MV
Value0.69
Score2/3
Weight12.80%
1M Return9.50%
Net profit / Total profit (%)
Value81.98
Score2/3
Weight1.08%
1M Return1.07%
Is GILD undervalued or overvalued?
  • GILD scores 3.99/10 on fundamentals and holds a Fair valuation at present. Backed by its 31.09% ROE, 27.88% net margin, 23.33 P/E ratio, 8.82 P/B ratio, and 5809.09% earnings growth, these metrics solidify its Netural investment rating.